01 / 07 / 2020
Initiate the new year with our next in vitro shuttle session on our validated M2 macrophage suppression assay, which will take place by early February – thereby providing an opportunity to timely and cost-effectively assess novel immunotherapeutics.
01 / 07 / 2020
Model responsiveness to standard Temozolomide and immune checkpoint inhibitors i.e. anti-CTLA4, anti-PD1, and anti-PDL1 antibodies, makes it well-suited for testing candidate compounds for their efficacy, as single agents and/or in combination, in promoting anti-tumor activity.
12 / 17 / 2019
"Comprehensive assessment of anti-tumor PDL1 blockade effect in a sarcoma mouse model"
12 / 08 / 2019
To deal with this level of complexity, it’s therefore critical to benefit from technological platform allowing for specific investigation in compartments of interest (eg. tumor vs stroma). Thanks to the GeoMx® platform (Nanostring Inc.), which combines the spatial resolution of immunohistofluorescence with the high-plex gene/protein expression analysis, the Digital Spatial Profiling (DSP) revolution has started.
12 / 03 / 2019
We will be attending the ESMO Immuno-Oncology Congress in Geneva, from December 11 to 14, 2019. We will be glad to take this opportunity to meet you there, describe our service offerings and approach your research projects.
11 / 21 / 2019
See our case study below or download our white paper!
Many cells of the innate immunity work in concert with the adaptive immune system to effectively afford protection.
10 / 28 / 2019
We are proud to announce that the French Ministry for Higher Education and Research has recognised Explicyte / Immusmol SAS as a "Credit Import Recherche" (CIR) approved research and development service provider.
10 / 24 / 2019
Nous sommes heureux de vous informer que le Ministère de l’Enseignement Supérieur, de la Recherche et de l’Innovation a remis un avis favorable au dossier de demande d’agrément Crédit Impôt Recherche déposé par Explicyte / Immusmol SAS.
10 / 09 / 2019
How about an opportunity to assess your compounds in a comprehensive and cost-effective manner?
09 / 12 / 2019
Immunotherapy-based anti-cancer strategies such as immune checkpoint inhibitors promote antitumor immune response driven by the mobilization of effector immune cell activity and/or reversal of immunosuppressive mechanisms.